Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board ...

The "Acromegaly - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. Key Highlights The Acromegaly market size in the 7MM was valued ...

Crinetics Pharmaceuticals, Inc.’s CRNX share price has surged by 8.07%, which has investors questioning if this is right time to sell.

The active substance of Oczyesa is octreotide hydrochloride, a synthetic derivative of naturally occurring somatostatin, a hypothalamic hormone. It works by reducing and normalizing IGF-1 and ...

Perspective Therapeutics, Inc.’s CATX share price has dipped by 5.35%, which has investors questioning if this is right time ...

The CAR product co-expresses a protein, called somatostatin receptor 2, which allows clinicians to monitor the therapy's effectiveness with a specialized positron emission tomography (PET ...

First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinica ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...

A panelist discusses how first-line treatment options for neuroendocrine tumors depend on tumor grade, disease extent, and symptoms, ranging from observation for asymptomatic cases to somatostatin ...

Using this approach, we identify somatostatin-28 as a potent inhibitor of both basal and stimulus-evoked serotonin release from EC cells and delineate the signaling pathway that underlies this ...